<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00311857</url>
  </required_header>
  <id_info>
    <org_study_id>Eudract-2005-003911-63</org_study_id>
    <secondary_id>PEI 119/01</secondary_id>
    <nct_id>NCT00311857</nct_id>
  </id_info>
  <brief_title>Safety Study of Cetuximab, Radiotherapy and Temozolomide in Primary Glioblastoma Multiforme(GERT)</brief_title>
  <official_title>Treatment of Primary Glioblastoma Multiforme With Cetuximab, Radiotherapy and Temozolomide (GERT) – Phase I/II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck KGaA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Heidelberg University</source>
  <brief_summary>
    <textblock>
      GERT is a one-armed single-center phase I/II trial. In a first step, dose-escalation of TMZ
      from 50 mg/m2 to 75mg/m2 together with radiotherapy and cetuximab will be performed. Should
      safety be proven, the phase II trial will be initiated with the standard dose of 75mg/m2 of
      TMZ. Cetuximab will be applied in the standard application dose of 400mg/m2 in week 1,
      thereafter at a dose of 250mg/m2 weekly. A total of 46 patients will be included into this
      phase I/II trial.

      Primary endpoints are feasibility and toxicity, secondary endpoints are overall and
      progression-free survival. An interim analysis will be performed after inclusion of 15
      patients into the main study. Patients’ enrolment will be performed over a period of 2 years.
      The observation time will end 2 years after inclusion of the last patient.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2006</start_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <enrollment>46</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt;= 18 and &lt; 70 years of age

          -  Karnofsky Performance Score &gt;= 60

          -  histologically confirmed supratentorial GBM

          -  interval between primary diagnosis and registration for the study &lt; 4 weeks

          -  patients will be included according to the incidental gender distribution for patients
             with GBM of ♀/♂ 2:3

          -  adequate blood values (not older than 14 days prior to initiation of RCHT)

          -  neutrophil count (ANC) ≥1500/mm3 or white blood cells (WBC) ≥2000/mm3

          -  platelets ≥100.000/mm3

          -  hemoglobin ≥10g/dL

          -  BUN &lt;1.5 times the upper range

          -  Total and direct bilirubin &lt;1.5times the upper laboratory limit

          -  Adequate liver enzymes &lt;3 times the upper laboratory limit

          -  Life expectancy &gt;12 weeks

          -  Written informed consent

        Exclusion Criteria:

          -  refusal of the patients to take part in the study

          -  previous radiotherapy of the brain or chemotherapy with DTIC or TMZ

          -  known allergy against extrinsical proteins

          -  previous chemotherapy or therapy with an EGFR-inhibitor

          -  Previous antibody therapy

          -  Patients who have not yet recovered from acute toxicities of prior therapies

          -  Acute infections requiring systemic application of antibiotics

          -  Frequent vomiting or a medical condition preventing the oral application of TMZ

          -  Clinically active kidney- liver or cardiac disease

          -  Known carcinoma &lt; 5 years ago (excluding Carcinoma in situ of the cervix, basal cell
             carcinoma, squamous cell carcinoma of the skin)

          -  HIV

          -  Pregnant or lactating women

          -  Participation in another clinical study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniela Schulz-Ertner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heidelberg University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniela Schulz-Ertner, MD</last_name>
    <phone>+49-6221-56</phone>
    <phone_ext>8201</phone_ext>
    <email>Daniela.Ertner@med.uni-heidelberg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephanie E Combs, MD</last_name>
    <phone>+49-6221-56</phone>
    <phone_ext>8201</phone_ext>
    <email>Stephanie.Combs@med.uni-heidelberg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniela Schulz-Ertner, MD</last_name>
      <phone>+49-6221-56</phone>
      <phone_ext>8201</phone_ext>
      <email>Daniela.Ertner@med.uni-heidelberg.de</email>
    </contact>
    <contact_backup>
      <last_name>Stephanie E Combs, MD</last_name>
      <phone>+49-6221-56</phone>
      <phone_ext>8201</phone_ext>
      <email>Stephanie.Combs@med.uni-heidelberg.de</email>
    </contact_backup>
    <investigator>
      <last_name>Daniela Schulz-Ertner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephanie E Combs, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2006</study_first_submitted>
  <study_first_submitted_qc>April 5, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2006</study_first_posted>
  <last_update_submitted>September 7, 2006</last_update_submitted>
  <last_update_submitted_qc>September 7, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 8, 2006</last_update_posted>
  <keyword>Cetuximab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

